RPAM
ECYT

Rhenman & Partners Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-49,297
Closed -$300K – 100
2014
Q3 		$300K Hold
49,297
– – 0.09% 99
2014
Q2 		$325K Sell
49,297
-19,491
-28% -$220K 0.1% 96
2014
Q1 		$1.64M Buy
68,788
+43,788
+175% +$635K 0.49% 69
2013
Q4 		$267K Buy
+25,000
New +$276K 0.1% 84

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rhenman & Partners Asset Management's ECYT Position: Q4 2014 in Review

Rhenman & Partners Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2014, closing a stake of 49,297 shares — an estimated $300K sold.

Rhenman & Partners Asset Management first reported a position in ECYT in Q4 2013 and held it in 4 quarters. The position peaked at $1.64M in Q1 2014. 100 funds tracked by Wall St. Rank hold ECYT as of Q4 2014.

  • Rhenman & Partners Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 49,297 Endocyte, Inc. Common Stock shares in Q4 2014, an estimated $300K.
  • Rhenman & Partners Asset Management first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 4 quarters.
  • Rhenman & Partners Asset Management's Endocyte, Inc. Common Stock position peaked at $1.64M in Q1 2014.
  • 100 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2014.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.